The aim of this work was to develop a novel (99m)Tc-labelled derivative based on
triphenylethylene for
breast cancer imaging. (99m)Tc-Clomiphene was obtained with a radiochemical yield of 94.4% by adding (99m)Tc to 1.5 mg
Clomiphene citrate in the presence of 10 μg
SnCl(2) at pH 7. The optimization of the labeling yield of
Clomiphene citrate, with (99m)Tc, is described. The reaction parameters that affect the labeling yield were studied to optimize the labeling conditions. Radiochemical purity of the final product has been verified by means of paper chromatography and paper electrophoresis. Ehrlich
Ascites Carcinoma (EAC) as a model of
breast cancer cells was injected intraperitoneally (IP) to produce
ascites and intramuscularly (IM) to produce solid
tumor. Biodistribution study was carried out by the injecting
solution of (99m)Tc-Clomiphene in normal and
tumor bearing mice. The uptake in
ascites was over 12.5 % injected dose per gram tissue
body weight, at 1hr after injection and above 12% in solid
tumor. The T/NT value for (99m)Tc-Clomiphene complex was found to be 5.5 ± 0.4 which was higher than that of the commercially available (99m)Tc-MIBI. This data revealed the localization of tracer in
tumor tissue with high percent sufficient to use (99m)Tc-Clomiphene as a promising tool for the diagnosis of
breast cancer.